Forest Laboratories has announced positive new clinical trial data supporting the efficacy of its drug levomilnacipran against major depressive disorder (MDD).
Developed in association with Pierre Fabre Medicament, the investigational agent was shown to significantly reduce depression symptoms in patients with MDD compared to placebo, delivering benefits within a week.
The new study represents the second phase III trial to demonstrate a positive outcome for levomilnacipran among this patient population, with further data analyses currently ongoing.
Dr Marco Taglietti, senior vice-president for research and development and president of the Forest Research Institute, said: "We have successfully completed two positive phase III studies for the treatment of MDD in adults and plan to file a new drug application for levomilnacipran with the Food and Drug Administration later this year."
Last month, Forest Laboratories expanded its UK product offering with the launch of Colobreathe, a new inhaler-based treatment for chronic lung infections among cystic fibrosis patients.